Japanese drugmaker Astellas Pharma announced this week that it's committed to achieving net zero greenhouse gas (GHG) emissions by 2050.
To do so, the company is committing to reducing 90% of its gas emissions in all scopes and neutralizing the remaining 10% by then. In its 2021 Corporate Strategic Plan, Astellas had vowed to “engage more with sustainability.”
When referring to scope emissions, scope 1 is direct emissions from in-house fuels, scope 2 is indirect emissions from purchased electricity and scope 3 refers to emissions in the supply chain of business activities. Studies have found that the pharmaceutical manufacturing industry is spending more than $1 billion on energy consumption every year, generating 55% more emissions than the automotive industry.
